Glioblastoma (GBM) is the most common and lethal tumor of the central nervous system. The
natural history of treated GBM remains very poor with 5-year survival rates of 5%. Survival …

Despite major advances in therapy, cancer continues to be a leading cause of mortality. In
addition, toxicities of traditional therapies pose a significant challenge to tolerability and …

Abstract Tumor Treating Fields (TTFields) are low intensity, intermediate frequency,
alternating electric fields. TTFields are a unique anti-mitotic treatment modality delivered in a …

Abstract Tumor Treating Fields (TTFields), a new modality of cancer treatment, are electric
fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment …

Numerical simulation of electromagnetic, thermal, and mechanical responses of the human
body to different stimuli in magnetic resonance imaging safety, antenna research …

Opinion statement Malignant gliomas remain a challenging cancer to treat due to limitations
in both therapeutic and efficacious options. Tumor treating fields (TTFields) have emerged …

Large-scale synchronization of neural oscillations is a key mechanism for functional
information exchange among brain areas. Dual-site Transcranial Alternating Current …

Tumor-treating fields (TTFields) are a cancer treatment modality that uses alternating electric
fields of intermediate frequency (~ 100-500 kHz) and low intensity (1-3 V/cm) to disrupt cell …

Abstract Non‐thermal, intermediate frequency (100–500 kHz) electrotherapies present a
unique therapeutic strategy to treat malignant neoplasms. Here, pulsed electric fields (PEFs) …

Glioblastoma (GBM) is a challenging cancer with poor prognosis. The classical standard for
treatment is safe resection, followed by concurrent chemoradiotherapy with subsequent …